Recruiting Venetoclax Combined With Olverembatinib and Predinisone in Treating Ph+ B-ALL NCT06754267 Conditions Hematologic Diseases, Hemic and Lymphatic Diseases, Immune System Diseases, +10 more Locations The First Affiliated Hospital, Zhejiang University School of Medicine — Hangzhou, Zhejiang, China View Trial Details
Recruiting Blinatumomab Plus Reduced-dose Chemotherapy in Treating B-ALL NCT06742515 Conditions Hematologic Diseases, Hemic and Lymphatic Diseases, Immune System Diseases, +10 more Locations The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310003 — Hangzhou, Zhejiang, China View Trial Details
Not Yet Recruiting A Study of Injectable BLB101 and Blincyto® in Adult Participants With R/R CD19+ B-ALL NCT07723911 Conditions Hematologic Diseases, Hemic and Lymphatic Diseases, Immune System Diseases, +10 more Locations Not specified View Trial Details
Active, Not Recruiting FT819 in Subjects With B-cell Malignancies NCT04629729 Conditions Chronic Disease, Chronic Lymphocytic Leukemia, Disease Attributes, +20 more Locations University of Alabama at Birmingham — Birmingham, Alabama, United States Mayo Arizona — Phoenix, Arizona, United States UC Davis — Davis, California, United States Scripps Green Hospital — La Jolla, California, United States View all 18 locations View more locations Show fewer locations Loading locations... View Trial Details
